MindImmune Therapeutics Appoints Brad Margus and Robert Michael Poole, MD FACP, to its Board of Directors Industry leaders bring deep background and experience, with Mr. Margus assuming role as Board Chair South Kingstown, RI – January 3, 2024 MindImmune Therapeutics,...
MindImmune Therapeutics Announces $12.4 million Series A Financing Company is pioneering a fundamentally new approach to treating Alzheimer’s disease Kingston, R.I. | June 13, 2022 MindImmune Therapeutics Inc., a drug discovery company pioneering a new approach to...
Bob Nelson, Frank Menniti, and Stevin Zorn met with the honorable Lt. Governor Daniel J. McKee on August 29, 2019 to discuss MindImmune’s current research progress.
MindImmune Licenses Preclinical Drug Discovery Programs from Lundbeck Will Develop Novel Therapeutics to Treat Neuropathic Pain and Huntington’s Disease Kingston, R.I., May 22, 2018 – MindImmune Therapeutics, Inc. and H. Lundbeck A/S(Lundbeck) today announced...
